Patients affected by psoriatic arthritis may benefit from both pharmacologic and non-pharmacologic treatments. In this slideshow, we outline the recommendations from the ACR and the National Psoriasis Foundation.
In rheumatology, there have been five new drug approvals in recent months for patients with rheumatoid arthritis, axial spondyloarthritis, plaque psoriasis, osteoporosis, among other conditions. Learn more about the new treatments and other drug news in this slideshow.
Axial spondyloarthritis (axSpA) is never a straightforward diagnosis. In this slideshow, we highlight 11 disease manifestations associated with axSpA.
In February, the Food and Drug Administration issued a boxed warning for the gout treatment febuxostat (Uloric, Takeda) citing a risk for cardiovascular disease. It was approved in 2009 for adult patients with gout. Learn more about this and the 2012 treatment guidelines for gout in this slideshow.
In this slideshow, we highlight some recent noteworthy advances in rheumatology, including new developments on the benefits of chiropractic care, how best to adopt methotrexate into a treatment plan, a possible new benefit for fatty acids, and much more.
To help clinicians provide guidance to patients interested in cannabis therapies, the Canadian Rheumatology Association has issued a position statement. In this slideshow, we highlight the recommendations.
By the time a patient is diagnosed with SLE, nephritis has already set in for 35 percent of patients. The American College of Rheumatology offers screening, treatment and management guidelines for lupus nephritis patients. In this slideshow, we review the options.
In this slideshow, we address the treatment recommendations for adults with active psoriatic arthritis despite previous treatment with biologics.
Increased cancer risk, a new measure for disease outcomes and a new treatment are among the developments in systemic lupus erythematosus (SLE) published in recent months. Learn more in this slideshow.
Calprotectin is a known marker of disease activity in rheumatoid arthritis (RA) and psoriatic arthritis (PsA). Now, researchers reporting in Arthritis Research and Therapy say that baseline calprotectin levels may predict disease relapse for RA and PsA patients on TNFi therapy. Learn more in this slideshow.